- Report
- October 2023
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- October 2023
- 181 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2020
- 58 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- November 2022
- 190 Pages
Global
From €2403EUR$2,490USD£2,062GBP
- Report
- June 2020
- 48 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Report
- May 2022
- 125 Pages
Europe
From €1448EUR$1,500USD£1,242GBP
- Report
- December 2021
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- August 2019
- 410 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- January 2024
- 95 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- November 2021
- 1032 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2023
- 280 Pages
Global
From €5531EUR$5,730USD£4,744GBP
- Book
- November 2022
North America
Procalcitonin is a biomarker used in genomics to measure the severity of bacterial infections. It is a peptide hormone produced by the thyroid gland and is released in response to bacterial infections. Procalcitonin is used to differentiate between bacterial and viral infections, and to monitor the progression of bacterial infections. It is also used to determine the need for antibiotics and to monitor the effectiveness of antibiotic therapy.
Procalcitonin testing is becoming increasingly popular in the genomics market due to its ability to provide accurate and timely diagnosis of bacterial infections. It is also used to reduce the risk of antibiotic resistance, as it can help to identify the most appropriate antibiotic for a particular infection.
Several companies are involved in the Procalcitonin market, including Abbott, Siemens, Roche, and Thermo Fisher Scientific. These companies offer a range of products, including Procalcitonin assays, kits, and reagents. Show Less Read more